OTCMKTS:HBPCF Helix BioPharma (HBPCF) Stock Price, News & Analysis $0.59 0.00 (0.00%) As of 05/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesBuy This Stock About Helix BioPharma Stock (OTCMKTS:HBPCF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Helix BioPharma alerts:Sign Up Key Stats Today's Range$0.59▼$0.5950-Day Range$0.45▼$0.5952-Week Range$0.45▼$0.92VolumeN/AAverage Volume1,071 shsMarket Capitalization$31.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Read More… Receive HBPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HBPCF Stock News HeadlinesHelix BioPharma Appoints New CEO to Propel Clinical AdvancementsApril 10, 2025 | tipranks.comHelix BioPharma Engages ITG for Market-Making ServicesApril 3, 2025 | tipranks.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 2, 2025 | Crypto 101 Media (Ad)Helix BioPharma Corp. Announces Key Decisions from Annual MeetingMarch 26, 2025 | tipranks.comHelix BioPharma Releases Interim Financial Statements for January 2025March 18, 2025 | tipranks.comHelix BioPharma to Present Promising Cancer Treatment Findings at EMIM 2025March 11, 2025 | tipranks.comHelix BioPharma Enhances Leadership with Oncology ExpertsMarch 11, 2025 | tipranks.comHelix BioPharma Extends Meeting for Key ApprovalsMarch 3, 2025 | tipranks.comSee More Headlines HBPCF Stock Analysis - Frequently Asked Questions How have HBPCF shares performed this year? Helix BioPharma's stock was trading at $0.4549 at the start of the year. Since then, HBPCF shares have increased by 29.7% and is now trading at $0.59. View the best growth stocks for 2025 here. How were Helix BioPharma's earnings last quarter? Helix BioPharma Corp. (OTCMKTS:HBPCF) issued its quarterly earnings data on Friday, March, 14th. The company reported ($0.02) EPS for the quarter. How do I buy shares of Helix BioPharma? Shares of HBPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/14/2025Today5/02/2025Next Earnings (Estimated)5/12/2025Fiscal Year End7/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:HBPCF CIKN/A Webwww.helixbiopharma.com Phone905-841-2300Fax905-841-2244Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,097.76% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,022,000Free Float48,992,000Market Cap$31.28 million OptionableNot Optionable Beta0.01 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:HBPCF) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.